Chandan S, Mohan BP, Kumar A, et al. - Researchers conducted the study for analyzing the safety and effectiveness of various biological agents in the treatment of chronic antibiotic refractory pouchitis (CARP). Multiple databases were explored until June 2020 for studies on the efficacy and safety of biological therapy in CARP, including antitumor necrosis factor-alpha agents [infliximab (IFX) and adalimumab (ADA)], vedolizumab (VDZ), and ustekinumab. Participants in the study were 311 patients. According to this systematic review and meta-analysis, pooled rate of clinical improvement was 71.4%, 58.2%, 47.9%, and clinical remission was 65.7%, 31%, 47.4% with IFX, ADA, and VDZ, respectively. Adverse events were recorded by 3.9% of patients. Overall, the authors concluded that biologic therapy is both safe and effective in the treatment of CARP.